Effect of Treatment for 12 Weeks With Rilapladib,a Lipoprotein-Associated Phospholipase A<sub>2</sub> Inhibitor,on Arterial Inflammation as Assessed With F-Fluorodeoxyglucose-Positron Emission Tomography Imaging期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Effect of Treatment for 12 Weeks With Rilapladib,a Lipoprotein-Associated Phospholipase A₂ Inhibitor,on Arterial Inflammation as Assessed With F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Authors:	Ahmed Tawakol Parmanand Singh James H.F. Rudd Joseph Soffer Gengqian Cai Esad Vucic Sarah P. Brannan Elizabeth A. Tarka Bonnie C. Shaddinger Lea Sarov-Blat Paul Matthews Sharath Subramanian Michael Farkouh Zahi A. Fayad

Affiliation:	^† Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts;^‡ Cardiac MR-PET-CT Program, Division of Cardiac Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts;^§ Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom;^‖ Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania;^¶ Division of Brain Sciences, Imperial College London, London, United Kingdom;^# Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York;^∗∗ Peter Munk Cardic Centre and the Heart and Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Ontario, Canada;^†† Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York

Abstract:

Keywords:
本文献已被 ScienceDirect 等数据库收录！